{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T11:36:58Z","timestamp":1792237018720,"version":"4.4.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17H00474"],"award-info":[{"award-number":["17H00474"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18H00420"],"award-info":[{"award-number":["18H00420"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.clinbiochem.2019.05.003","type":"journal-article","created":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T23:11:44Z","timestamp":1557357104000},"page":"8-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Relationships between concomitant biologic DMARDs and prednisolone administration and blood tacrolimus exposure or serum CYP3A4\/5-related markers in rheumatoid arthritis patients"],"prefix":"10.1016","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7447-3789","authenticated-orcid":false,"given":"Takafumi","family":"Naito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Ohshiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Torikai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyoshi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.clinbiochem.2019.05.003_bb0005","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3727\/000000001783986387","article-title":"Inhibition of cytokine production and cytokine-stimulated T-cell activation by FK506 (tacrolimus)1","volume":"10","author":"Almawi","year":"2001","journal-title":"Cell Transplant."},{"issue":"10","key":"10.1016\/j.clinbiochem.2019.05.003_bb0010","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1002\/art.11257","article-title":"Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study","volume":"48","author":"Kremer","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"12","key":"10.1016\/j.clinbiochem.2019.05.003_bb0015","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1002\/art.11363","article-title":"Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial","volume":"48","author":"Yocum","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.clinbiochem.2019.05.003_bb0020","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2133\/dmpk.22.328","article-title":"Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics","volume":"22","author":"Iwasaki","year":"2007","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.clinbiochem.2019.05.003_bb0025","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0009-9236(03)00168-1","article-title":"Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus","volume":"74","author":"Hesselink","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.clinbiochem.2019.05.003_bb0030","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00008571-200403000-00002","article-title":"The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients","volume":"14","author":"Haufroid","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.clinbiochem.2019.05.003_bb0035","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cca.2015.03.021","article-title":"ABCB1 genetic variant and its associated tacrolimus pharmacokinetics affect renal function in patients with rheumatoid arthritis","volume":"445","author":"Naito","year":"2015","journal-title":"Clin. Chim. Acta"},{"issue":"6","key":"10.1016\/j.clinbiochem.2019.05.003_bb0040","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1136\/ard.59.6.439","article-title":"Interindividual and intra-articular variation of proinflammatory cytokines in patients with rheumatoid arthritis: potential implications for treatment","volume":"59","author":"Ulfgren","year":"2000","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.clinbiochem.2019.05.003_bb0045","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.dmpk.2014.09.004","article-title":"Effects of cytokines on CYP3A4 expression and reversal of the effects by anti-cytokine agents in the three-dimensionally cultured human hepatoma cell line FLC-4","volume":"30","author":"Mimura","year":"2015","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"9","key":"10.1016\/j.clinbiochem.2019.05.003_bb0050","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1124\/dmd.107.015511","article-title":"Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes","volume":"35","author":"Aitken","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.clinbiochem.2019.05.003_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2012.00008","article-title":"Immunological response as a source to variability in drug metabolism and transport","volume":"3","author":"Christensen","year":"2012","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.clinbiochem.2019.05.003_bb0060","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/clpt.2013.79","article-title":"A physiologically based pharmacokinetic modeling approach to predict disease-drug interactions: suppression of CYP3A by IL-6","volume":"94","author":"Machavaram","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.clinbiochem.2019.05.003_bb0065","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.bjc.6600448","article-title":"Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response","volume":"87","author":"Rivory","year":"2002","journal-title":"Br. J. Cancer"},{"issue":"12","key":"10.1016\/j.clinbiochem.2019.05.003_bb0070","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00228-016-2116-z","article-title":"Relationships between oxycodone pharmacokinetics, central symptoms, and serum interleukin-6 in cachectic cancer patients","volume":"72","author":"Sato","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.clinbiochem.2019.05.003_bb0075","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/clpt.2011.35","article-title":"Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis","volume":"89","author":"Schmitt","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.clinbiochem.2019.05.003_bb0080","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/jcph.561","article-title":"Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach","volume":"55","author":"Zhuang","year":"2015","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.clinbiochem.2019.05.003_bb0085","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cca.2014.12.024","article-title":"Impact of inflammation and concomitant glucocorticoid administration on plasma concentration of triazole antifungals in immunocompromised patients","volume":"441","author":"Naito","year":"2015","journal-title":"Clin. Chim. Acta"},{"issue":"15","key":"10.1016\/j.clinbiochem.2019.05.003_bb0090","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2165\/00003088-200342150-00003","article-title":"Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes","volume":"42","author":"Wang","year":"2003","journal-title":"Clin. Pharmacokinet."},{"issue":"10","key":"10.1016\/j.clinbiochem.2019.05.003_bb0095","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.1073\/pnas.93.10.4666","article-title":"Dexamethasone responsiveness of a major glucocorticoid-inducible CYP3A gene is mediated by elements unrelated to a glucocorticoid receptor binding motif","volume":"93","author":"Huss","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.clinbiochem.2019.05.003_bb0100","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s40262-016-0462-8","article-title":"Disease-drug interaction of sarilumab and simvastatin in patients with rheumatoid arthritis","volume":"56","author":"Lee","year":"2017","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.clinbiochem.2019.05.003_bb0105","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1365-2125.2008.03309.x","article-title":"4\u03b2-hydroxycholesterol as an endogenous marker for CYP3A4\/5 activity. Stability and half-life of elimination after induction with rifampicin","volume":"67","author":"Diczfalusy","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2019.05.003_bb0110","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.bcp.2012.03.017","article-title":"Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation","volume":"84","author":"Thirumaran","year":"2012","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.clinbiochem.2019.05.003_bb0115","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/jn\/135.2.317","article-title":"Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D","volume":"135","author":"Hollis","year":"2005","journal-title":"J. Nutr."},{"issue":"12","key":"10.1016\/j.clinbiochem.2019.05.003_bb0120","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/aje\/kwr258","article-title":"Seasonal variation in 25-hydroxyvitamin D concentrations in the cardiovascular health study","volume":"174","author":"Shoben","year":"2011","journal-title":"Am. J. Epidemiol."},{"issue":"8","key":"10.1016\/j.clinbiochem.2019.05.003_bb0125","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00228-008-0492-8","article-title":"CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4\u03b2-hydroxycholesterol levels","volume":"64","author":"Josephson","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.clinbiochem.2019.05.003_bb0130","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.dmpk.2016.04.001","article-title":"Relationship between the plasma fentanyl and serum 4\u03b2-hydroxycholesterol based on CYP3A5 genotype and gender in patients with cancer pain","volume":"31","author":"Ishida","year":"2016","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.clinbiochem.2019.05.003_bb0135","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.192","article-title":"miRNA-27b levels are associated with CYP3A activity in vitro and in vivo","volume":"3","author":"Ekstr\u00f6m","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"issue":"11","key":"10.1016\/j.clinbiochem.2019.05.003_bb0140","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1111\/bcp.13343","article-title":"Pretransplant 4\u03b2-hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation","volume":"83","author":"Vanhove","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2019.05.003_bb0145","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/cts.12431","article-title":"4\u03b2-hydroxycholesterol level in patients with rheumatoid arthritis before vs. after initiation of bDMARDs and correlation with inflammatory state","volume":"10","author":"Wollmann","year":"2017","journal-title":"Clin. Transl. Sci."},{"issue":"10","key":"10.1016\/j.clinbiochem.2019.05.003_bb0150","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1124\/dmd.118.082065","article-title":"Associations between cytokine levels and CYP3A4 phenotype in patients with rheumatoid arthritis","volume":"46","author":"Wollmann","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.clinbiochem.2019.05.003_bb0155","series-title":"Drug Interactions: Cytochrome P450 Drug Interaction Table","author":"Flockhart","year":"2007"},{"issue":"5\u20136","key":"10.1016\/j.clinbiochem.2019.05.003_bb0160","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.clinbiochem.2010.12.020","article-title":"Suitability of chemiluminescent enzyme immunoassay for the measurement of blood tacrolimus concentrations in rheumatoid arthritis","volume":"44","author":"Hirano","year":"2011","journal-title":"Clin. Biochem."},{"issue":"6","key":"10.1016\/j.clinbiochem.2019.05.003_bb0165","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.dmpk.2015.08.008","article-title":"CYP3A activity based on plasma 4\u03b2-hydroxycholesterol during the early postpartum period has an effect on the plasma disposition of amlodipine","volume":"30","author":"Naito","year":"2015","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.clinbiochem.2019.05.003_bb0170","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/00008571-200206000-00009","article-title":"Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population","volume":"12","author":"Fukuen","year":"2002","journal-title":"Pharmacogenetics"},{"issue":"11","key":"10.1016\/j.clinbiochem.2019.05.003_bb0175","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nrrheum.2014.121","article-title":"Rheumatoid arthritis and metabolic syndrome","volume":"10","author":"Kerekes","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"issue":"11","key":"10.1016\/j.clinbiochem.2019.05.003_bb0180","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1136\/annrheumdis-2017-211708","article-title":"Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis","volume":"76","author":"Robertson","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.clinbiochem.2019.05.003_bb0185","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1111\/bcp.13248","article-title":"The CYP3A biomarker 4\u03b2-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation","volume":"83","author":"St\u00f8rset","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.clinbiochem.2019.05.003_bb0190","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1124\/dmd.111.038679","article-title":"Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture","volume":"39","author":"Dickmann","year":"2011","journal-title":"Drug Metab. Dispos."},{"issue":"10","key":"10.1016\/j.clinbiochem.2019.05.003_bb0195","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clinbiochem.2019.05.003_bb0200","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.intimp.2005.05.010","article-title":"Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family","volume":"5","author":"Mihara","year":"2005","journal-title":"Int. Immunopharmacol."},{"issue":"4","key":"10.1016\/j.clinbiochem.2019.05.003_bb0205","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1124\/dmd.113.051136","article-title":"Serum levels of 25-hydroxyvitamin D and the CYP3A biomarker 4\u03b2-hydroxycholesterol in a high-dose vitamin D supplementation study","volume":"41","author":"Bj\u00f6rkhem-Bergman","year":"2013","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.clinbiochem.2019.05.003_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nutres.2015.10.006","article-title":"Association between 25-hydroxyvitamin D and inflammatory biomarker levels in a cross-sectional population-based study, S\u00e3o Paulo, Brazil","volume":"36","author":"de Souza","year":"2016","journal-title":"Nutr. Res."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912018314140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912018314140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:54:30Z","timestamp":1757865270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912018314140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":42,"alternative-id":["S0009912018314140"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2019.05.003","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationships between concomitant biologic DMARDs and prednisolone administration and blood tacrolimus exposure or serum CYP3A4\/5-related markers in rheumatoid arthritis patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2019.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}